INRLF (Valneva SE) Tariff Resilience Score: 6/10 (As of Jul. 03, 2026)


INRLF Valneva SE INRLF
60 GF Score
Price $2.62
GF Value $2.84
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Tariff Resilience Score?

Valneva SE INRLF 60 Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus rates INRLF with a GF Score™ of 60/100 and a GF Value™ of $2.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,374 Biotechnology companies, Valneva SE ranks better than 75.98% on this metric.

Valneva SE has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Valneva SE has Valneva SE, a biotech firm, has moderate exposure to tariffs due to its reliance on global supply chains for raw materials. However, its focus on vaccines, which are often exempt from tariffs, provides some resilience. Historical impacts have been minimal, and the company can leverage alternative suppliers if needed.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Valneva SE might have Average Resilient.

Valneva SE  (OTCPK:INRLF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Valneva SE Tariff Resilience Score Related Terms

INRLF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Valneva SE's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Valneva SE's Tariff Resilience Score falls into.


INRLF
60GF Score
Valneva SE INRLF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Valneva SE (INRLF) has a Tariff Resilience Score of 6 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Valneva SE ranks #330 out of 1374 companies in the Biotechnology industry, placing it in the top 24%.
Is Valneva SE's Tariff Resilience Score too high?
Valneva SE's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Valneva SE's value of 6 is 50% above this industry median. Based on the distribution chart, Valneva SE ranks #330 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valneva SE has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #330 out of 1374 companies for Tariff Resilience Score. This places Valneva SE in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Valneva SE's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.84, compared to a current price of $2.62 — trading 7.7% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Valneva SE's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Valneva SE (INRLF), the current Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Tariff Resilience Score: 6
  • GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
  • GF Score™: 60/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1374)

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score

Get the complete analysis for INRLF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.84
GF Value